This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CLEAR Outcomes study - bempedoic acid and cardiovascular outcomes in statin intolerant patients

Authoring team

CLEAR Outcomes study - bempedoic acid and cardiovascular outcomes in statin intolerant patients

Bempedoic acid is a first-in-class, small-molecule inhibitor of ATP-citrate lyase, a component of the cholesterol biosynthesis pathway that works upstream of beta-hydroxy beta-methylglutaryl-coenzyme A.

  • Bempedoic acid is a prodrug that is activated by very-longchain acyl-CoA synthetase-1, an enzyme that is not present in skeletal muscle
    • therefore bempedoic acid acts on the same pathway as statins - however lack of the activating enzyme in skeletal muscle may prevent the muscular adverse effects associated with statins (1)

    • in phase 2 and phase 3 clinical trials, bempedoic acid significantly reduced atherogenic lipoproteins and high-sensitivity C-reactive protein (hsCRP) levels, and was associated with a low risk for adverse events typically associated with statins such as muscle-related symptoms and new-onset diabetes mellitus

Bempedoic acid - CLEAR Outcomes study (cardiovascular outcomes in statin intolerant patients)

  • study design
    • randomized, double-blind, placebo-controlled clinical trial
    • included patients must have all of the following:
      • (i) established atherosclerotic cardiovascular disease or have a high risk of developing atherosclerotic cardiovascular disease,
      • (ii) documented statin intolerance, and
      • (iii) an LDL-C >=2.6 mmol/l on maximally-tolerated lipid-lowering therapy
      • randomized to treatment with bempedoic acid 180 mg daily or matching placebo on a background of guideline-directed medical therapy

      • primary endpoint was 4-component MACE, defined as nonfatal MI, nonfatal stroke, coronary revascularization or CV death
      • trial was designed to continue until 1620 patients experience a primary endpoint, with a minimum of 810 hard ischemic events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) and minimum treatment duration of 36 months and a projected median treatment exposure of 42 months (2)
  • study results (3)
    • total of 13,970 patients underwent randomization
      • 6992 were assigned to the bempedoic acid group and 6978 to the placebo group
      • median duration of follow-up was 40.6 months
      • mean LDL cholesterol level at baseline was 3.5 mmol/l in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 0.75 mmol/l
      • at 6 months, bempedoic acid reduced LDL-c by 21.7% and hsCRP (high sensitivity CRP) by 22.2%
        • in comparison, a 0.6% reduction in LDL-c and an increase of 2.2% in hsCRP was observed in the placebogroup at 6 months
      • incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; (absolute risk reduction of 1.6%) Number needed to treat (NNT) was 63
        • hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P=0.004)
      • the first 3 secondary endpoints were reduced as well by bempedoic acid:
        • a 15% reduction in 3-component MACE (HR 0.85, 95%CI 0.76-0.96, P=0.006, ARR 1.3%),
        • a 23% reduction in fatal or nonfatal MI (HR 0.77, 95%CI 0.66-0.91, P=0.002, ARR 1.1%) , and a
        • 19% reduction in coronary revascularization (HR 0.81, 95%CI 0.72-0.92, P=0.001, ARR 1.4%).
      • bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause
      • incidences of gout (3.1% vs. 2.1%) Number needed to harm (NNH) = 100, cholelithiasis (2.2% vs 1.2%) NNH =100, renal impairment (11.5% vs. 8.6%) (NNH = 34), elevated hepatic-enzyme level (4.5% vs. 3.0%) (NNH=66) and hyperuricemia (10.9% vs. 5.6%) (NNH=19) were higher in the bempedoic acid group compared to the placebo group

  • conclusion:
    • CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death

In a sub-analysis of bempedoic acid in primary prevention of cardiovascular disease in statin-intolerant patients (3):

  • 4206 participants were enrolled with high cardiovascular risk but without a prior cardiovascular event. In this subgroup, bempedoic acid treatment, 180 mg daily, was associated with a significant reduction in major cardiovascular events (hazard ratio, 0.70)
    • mean participant age was 68 years, 59% were female, and 66% had diabetes
    • follow-up for a median of 39.9 months was associated with a significant risk reduction for the primary end point (111 events [5.3%] vs 161 events [7.6%]; adjusted hazard ratio [HR], 0.70 [95% CI, 0.55-0.89] NNT=43; P=.002)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.